Clinical trial
Best Tolerability: 50mg Twice Daily Versus 100 mg in the Evening Versus 25 mg Twice Daily Versus Placebo in Younger Women in North America
NCT00360555 is registered in ClinicalTrials.gov with Sprout Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Best Tolerability: 50mg Twice Daily Versus 100 mg in the Evening Versus 25 mg Twice Daily Versus Placebo in Younger Women in North America
- Lead sponsor
- Sprout Pharmaceuticals, Inc
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 31, 2006
- Completion date
- March 31, 2008
- Enrollment
- 1,584 (actual)
- Sites
- 77
Conditions
As the registry lists them; a condition with its own page is linked.